Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neurofibroma × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 34 Carcinoma, Renal Cell 29 Neoplasms 17 Kidney Neoplasms 15 Neuroendocrine Tumors 13 Neoplasm Metastasis 12 Tuberous Sclerosis 8 Prostatic Neoplasms 8 Carcinoma 8 Lymphoma, Mantle-Cell 7 Hodgkin Disease 7 Waldenstrom Macroglobulinemia 6 Recurrence 6 Lymphoma, Large B-Cell, Diffuse 6 Head and Neck Neoplasms 6 Glioma 6 Triple Negative Breast Neoplasms 5 Ovarian Neoplasms 5 Lymphoma 5 Glioblastoma 5 Colorectal Neoplasms 5 Carcinoma, Neuroendocrine 5 Brain Neoplasms 5 Astrocytoma 5 Sezary Syndrome 4 Sarcoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Mycosis Fungoides 4 Melanoma 4

Interventions

mirdametinib 2 tipifarnib 1 peginterferon alfa-2b 1 nilotinib 1 binimetinib 1 Vincristine 1 Temozolomide 1 Radiosurgery 1 Imatinib Mesylate 1 Everolimus 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡